Related references
Note: Only part of the references are listed.Ubiquitin Makes Its Mark on Immune Regulation
Barbara A. Malynn et al.
IMMUNITY (2010)
Chemokine and chemokine receptor expression analysis in target organs of acute graft-versus-host disease
A. Bouazzaoui et al.
GENES AND IMMUNITY (2009)
Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity
Xiangling Wang et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Graft-versus-host disease
James L. M. Ferrara et al.
LANCET (2009)
Impaired Effector Memory T-Cell Regulation Facilitates Graft Versus Host Disease in CCR7-Deficient Bone Marrow Transplant Chimeras
Saskia C. A. de Jager et al.
TRANSPLANTATION (2009)
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells
Carsten Berges et al.
IMMUNOLOGY (2008)
A New Approach to the Blocking of Alloreactive T Cell-Mediated Graft-versus-Host Disease by In Vivo Administration of Anti-CXCR3 Neutralizing Antibody
Shan He et al.
JOURNAL OF IMMUNOLOGY (2008)
The Erk2 MAPK Regulates CD8 T Cell Proliferation and Survival
Warren N. D'Souza et al.
JOURNAL OF IMMUNOLOGY (2008)
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells
Changyou Li et al.
MOLECULAR CANCER THERAPEUTICS (2008)
CCR7 and its ligands:: balancing immunity and tolerance
Reinhold Foerster et al.
NATURE REVIEWS IMMUNOLOGY (2008)
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib
D. A. Fennell et al.
ONCOGENE (2008)
CXCL 10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation
Karen P. Piper et al.
BLOOD (2007)
Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse
B. Wysoczanska et al.
TRANSPLANTATION PROCEEDINGS (2007)
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications
Radek Spisek et al.
BLOOD (2007)
Ubiquitin and ubiquitin-like proteins in cancer pathogenesis
Daniela Hoeller et al.
NATURE REVIEWS CANCER (2006)
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Alessio Nencioni et al.
BLOOD (2006)
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
Tommaso Caravita et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines
B Blanco et al.
BLOOD (2006)
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, velcade)
Lana Y. Schumacher et al.
JOURNAL OF IMMUNOLOGY (2006)
Increase of CCR7- CD45RA+ CD8 T cells (TEMRA) in chronic graft-versus-host disease
M D'Asaro et al.
LEUKEMIA (2006)
NF-κB as a target for the prevention of graft-versus-host disease:: comparative efficacy of bortezomib and PS-1145
S Vodanovic-Jankovic et al.
BLOOD (2006)
A revision of Billingham's tenets: The central role of lymphocyte migration in acute graft-versus-host disease
R Sackstein
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Pathophysiology of graft-versus-host disease
JLM Ferrara et al.
SEMINARS IN HEMATOLOGY (2006)
In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets
A Beilhack et al.
BLOOD (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation
M Jaksch et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
A Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
Blockade of CXCR3 receptor: Ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome
GC Hildebrandt et al.
JOURNAL OF IMMUNOLOGY (2004)
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
K Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4+ effector memory cells relative to central memory cells
K Yamashita et al.
BLOOD (2004)
Role of CXCR3-induced donor T-cell migration in acute GVHD
U Duffner et al.
EXPERIMENTAL HEMATOLOGY (2003)
Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays
T Ichiba et al.
BLOOD (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
